The 3 most recent market catalysts affecting $APYX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 92
Apyx Medical Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $13.884M Beat $13.175M Estimate
Apyx Medical's Q2 earnings report shows a beat on both EPS and sales estimates. The company reported a smaller loss per share than anticipated and significantly higher sales, indic…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 55
Apyx Medical Affirms FY2026 Sales Guidance of $59.000M-$60.000M vs $59.554M Est
Apyx Medical's 8-K filing indicates that the company is reaffirming its sales guidance for fiscal year 2026, keeping the range at $59.000 million to $60.000 million. This is a non-…
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 65
HC Wainwright & Co. Initiates Coverage On Apyx Medical with Buy Rating, Announces Price Target of $7
HC Wainwright & Co. analyst Yi Chen initiated coverage on Apyx Medical (APYX) with a 'Buy' rating and set a price target of $7. This event is significant for APYX as new analyst co…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.